Sexually transmitted infection testing and diagnosis in adolescents and young adults with sickle cell disease
Pediatric Blood & Cancer · 2024
DOI: 10.1002/pbc.31240 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Joseph Walden und 4 weiteren Autor:innen. Beteiligte Einrichtung: Abigail Wexner Research Institute, Center for Child Health Equity and Outcomes Research, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Sexually Transmitted Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Background
Sexually transmitted infections (STIs) are common and disproportionately affect Black adolescents and young adults (AYAs). Less is known about STIs among Black AYAs with chronic conditions, such as sickle cell disease (AYAs‐SCD). This study compared STI testing and diagnosis between AYAs‐SCD and their peers, overall and among STI‐related encounters. Procedure This retrospective, cross‐sectional study used diagnosis and billing codes in the Pediatric Health Information System (PHIS) to identify inpatient and emergency department encounters from January 1, 2022 to May 31, 2023 among all AYAs 15–24 years and those with STI‐related diagnoses (e.g., “cystitis”). STI testing and diagnosis rates were compared between AYAs‐SCD, non‐Black AYAs, and Black AYAs, controlling for age, sex, and encounter setting.
Results
We identified 3602 AYAs‐SCD, 177,783 Black AYAs, and 534,495 non‐Black AYAs. AYAs‐SCD were less likely to be tested for STIs than non‐Black AYAs (odds ratio [OR] = 0.26; adj. p < .001) and Black AYAs (OR = 0.53; adj. p < .001). When tested, AYAs‐SCD were more likely to be diagnosed with an STI than non‐Black AYAs (OR = 2.39; adj. p = .006) and as likely as Black AYAs (OR = 0.67; adj. p = .15). Among STI‐related encounters, AYAs‐SCD were less likely to be tested than non‐Black AYAs (OR = 0.18; adj. p < .001) and Black AYAs (OR = 0.44; adj. p < .001). No significant differences in STI diagnoses were found in this subset between AYAs‐SCD and non‐Black AYAs (OR = 0.32; adj. p = .28) or Black AYAs (OR = 1.07; adj. p = .99).
Conclusions
STI care gaps may disproportionately affect AYAs‐SCD. STIs should be considered when evaluating symptomatic AYAs‐SCD in acute settings. More research is needed to further contextualize STI care for AYAs‐SCD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Abigail Wexner Research Institute, Center for Child Health Equity and Outcomes Research, Columbus, Ohio, USA.
- Division of Hematology/Oncology/BMT, Department of Pediatrics, Nationwide Children's Hospital, Columbus, Ohio, USA.
- Division of Adolescent Medicine, Department of Pediatrics, Nationwide Children's Hospital, Columbus, Ohio, USA.
- Abigail Wexner Research Institute, Center for Biobehavioral Health, Columbus, Ohio, USA.
- Division of Endocrinology, Department of Pediatrics, Nationwide Children's Hospital, Columbus, Ohio, USA.
ORCID-Profile: Joseph Walden, Joseph R Stanek, Leena Nahata, Susan E Creary
Förderung
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
- National Cancer Institute
Zitieren
APA
Walden, J., Stanek, J. R., Ebersole, A. M., Nahata, L., & Creary, S. E. (2024). Sexually transmitted infection testing and diagnosis in adolescents and young adults with sickle cell disease. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31240
Vancouver
Walden J, Stanek JR, Ebersole AM, Nahata L, Creary SE. Sexually transmitted infection testing and diagnosis in adolescents and young adults with sickle cell disease. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.31240
BibTeX
@article{Walden2024,
author = {Walden, Joseph and Stanek, Joseph R and Ebersole, Ashley M and Nahata, Leena and Creary, Susan E},
title = {Sexually transmitted infection testing and diagnosis in adolescents and young adults with sickle cell disease},
journal = {Pediatric Blood & Cancer},
year = {2024},
doi = {10.1002/pbc.31240}
}
EUVIMED